Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Inclusion Criteria: * Female or male participants, aged at least 18 years (no upper limit of age) * ECOG PS 0 or 1 * Life expectancy of at least 3 months * Participants with histologically or cytologically documented metastatic or refractory/recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal. * Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression * Prior therapy: * No more than one prior systemic treatment for recurrent /metastatic disease * Prior treatment for recurrent or metastatic disease is not required for: * Participants with recurrence/progression within 6 months after completion of prior multimodal therapy for localized or locally advanced disease * Participants who are unsuitable for platinum-based therapy * Participants who refuse chemotherapy or other standard therapies for the treatment of metastatic or recurrent disease * Limited hepatic disease for participants with liver metastases at baseline * Availability of tumor tissue from biopsy * At least one measurable lesion by CT scan according to RECIST 1.1. * Adequate hematological, hepatic and renal function * Negative blood pregnancy test at screening for women of childbearing potential * Highly effective contraception for both male and female participants if the risk of conception exists during the study period and for 3 months after the last study treatment administration Exclusion Criteria: * Prior expos…